Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • EP full-text search
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Technology insight reports
    • Data
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Technology platforms
      • Overview
      • Plastics in transition
      • Water innovation
      • Space innovation
      • Technologies combatting cancer
      • Firefighting technologies
      • Clean energy technologies
      • Fighting coronavirus
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
    Image
    Plastics in Transition

    Technology insight report on plastic waste management

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • Find a professional representative
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact with us on your files
      • Online Filing & fee payment outages
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Find out how the Unitary Patent can enhance your IP strategy

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • Guidelines
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National measures relating to the Unitary Patent
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
    Image
    Law and practice scales 720x237

    Keep up with key aspects of selected BoA decisions with our monthly "Abstracts of decisions”

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • European Inventor Network
      • The 2024 event
    • Young Inventor Prize
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    From ideas to inventions: tune into our podcast for the latest in tech and IP

  • Learning

    Learning

    The European Patent Academy – the point of access to your learning

    Go to overview 

    • Overview
    • Learning activities and paths
      • Overview
      • Learning activities
      • Learning paths
    • EQE and EPAC
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Overview
      • Business and IP managers
      • EQE and EPAC Candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)
    Image
    Patent Academy catalogue

    Have a look at the extensive range of learning opportunities in the European Patent Academy training catalogue

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Overview
      • Communiqués
      • Calendar
      • Documents and publications
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Sustainability at the EPO
      • Overview
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Overview
      • Innovation actors
      • Policy and funding
      • Tools
      • About the Observatory
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Sustainable Procurement Policy
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
      • "Long Night"
    Image
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Track the latest tech trends with our Patent Index

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
  • New to patents
    • Go back
    • Overview
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Your business and patents
    • Is it patentable?
    • Are you first?
    • Why do we have patents?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Release notes
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • EP full-text search
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Technology insight reports
    • Data
      • Go back
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
        • Boards of Appeal decisions
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server web service
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Technology platforms
      • Go back
      • Overview
      • Plastics in transition
        • Go back
        • Overview
        • Plastics waste recovery
        • Plastics waste recycling
        • Alternative plastics
      • Innovation in water technologies
        • Go back
        • Overview
        • Clean water
        • Protection from water
      • Space innovation
        • Go back
        • Overview
        • Cosmonautics
        • Space observation
      • Technologies combatting cancer
        • Go back
        • Overview
        • Prevention and early detection
        • Diagnostics
        • Therapies
        • Wellbeing and aftercare
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
    • Helpful resources
      • Go back
      • Overview
      • First time here?
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
          • Introductory brochures
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Exchange data with us using an API
          • Go back
          • Release notes
      • Get access
        • Go back
        • Overview
        • Release notes
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact with us on your files
        • Go back
        • Release notes
      • Online Filing & fee payment outages
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Overview
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • Guidelines
        • Go back
        • Overview
        • EPC Guidelines
        • PCT-EPO Guidelines
        • Unitary Patent Guidelines
        • Guidelines revision cycle
        • Consultation results
        • Summary of user responses
        • Archive
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
        • Go back
        • Travaux préparatoires to UP and UPC
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the inventors
      • Nominations
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • The 2024 event
    • Young Inventors Prize
      • Go back
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Water-related technologies
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Overview
        • CodeFest 2024 on generative AI
        • CodeFest 2023 on Green Plastics
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • Learning activities and paths
      • Go back
      • Overview
      • Learning activities: types and formats
      • Learning paths
    • EQE and EPAC
      • Go back
      • Overview
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Compendium
          • Go back
          • Overview
          • Paper F
          • Paper A
          • Paper B
          • Paper C
          • Paper D
          • Pre-examination
        • Candidates successful in the European qualifying examination
        • Archive
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventor's handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • EQE and EPAC Candidates
        • Go back
        • Overview
        • Paper F brain-teasers
        • Daily D questions
        • European qualifying examination - Guide for preparation
        • EPAC
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Modular IP Education Framework (MIPEF)
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
        • PATLIB Knowledge Transfer to Africa
          • Go back
          • The PATLIB Knowledge Transfer to Africa initiative (KT2A)
          • KT2A core activities
          • Success story: Malawi University of Science and Technology and PATLIB Birmingham
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Official celebrations
      • Overview
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Go back
      • Overview
      • Communiqués
        • Go back
        • 2024
        • Overview
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
        • Go back
        • Driver 1: People
        • Driver 2: Technologies
        • Driver 3: High-quality, timely products and services
        • Driver 4: Partnerships
        • Driver 5: Financial sustainability
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Sustainability at the EPO
      • Go back
      • Overview
      • Environmental
        • Go back
        • Overview
        • Inspiring environmental inventions
      • Social
        • Go back
        • Overview
        • Inspiring social inventions
      • Governance and Financial sustainability
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Dynamic Purchasing System (DPS) publications
      • Sustainable Procurement Policy
      • About eTendering
      • Invoicing
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Quality Action Plan
        • Quality dashboard
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
        • Integrated management at the EPO
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
        • Surveys
          • Go back
          • Overview
          • Detailed methodology
          • Search services
          • Examination services, final actions and publication
          • Opposition services
          • Formalities services
          • Customer services
          • Filing services
          • Key Account Management (KAM)
          • Website
          • Archive
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Go back
      • Overview
      • Innovation against cancer
      • Innovation actors
        • Go back
        • Overview
        • Startups and SMEs
      • Policy and funding
        • Go back
        • Overview
        • Financing innovation programme
          • Go back
          • Overview
          • Our studies on the financing of innovation
          • EPO initiatives for patent applicants
          • Financial support for innovators in Europe
        • Patents and standards
          • Go back
          • Overview
          • Publications
          • Patent standards explorer
      • Tools
        • Go back
        • Overview
        • Deep Tech Finder
      • About the Observatory
        • Go back
        • Overview
        • Work plan
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Go back
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Previous exhibitions
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Long Night"
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Information from the Boards of Appeal
    • Procedure
    • Oral proceedings
    • About the Boards of Appeal
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2025
      • Archive
    • Annual list of cases
    • Communications
    • Annual reports
      • Go back
      • Overview
    • Publications
      • Go back
      • Abstracts of decisions
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Patent Knowledge Products and Services
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Glossary
    • RSS feeds
Board of Appeals
Decisions

Recent decisions

Overview
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Home
  2. T 0249/88 14-02-1989
Facebook X Linkedin Email

T 0249/88 14-02-1989

European Case Law Identifier
ECLI:EP:BA:1989:T024988.19890214
Date of decision
14 February 1989
Case number
T 0249/88
Petition for review of
-
Application number
83870003.7
IPC class
A61K 37/36
Language of proceedings
EN
Distribution
-

Download and more information:

Decision in EN 639.16 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

Method for improved bovine milk production

Applicant name
Monsanto Company
Opponent name
-
Board
3.3.01
Headnote
-
Relevant legal provisions
European Patent Convention Art 56 1973
Keywords

Inventive step (no), obvious to try-

reasonable expectation of success

Catchword
-
Cited decisions
T 0003/82
T 0192/82
Citing decisions
T 0406/00
T 0946/00
T 0464/02
T 0200/05
T 1233/05
T 0345/07
T 0737/07
T 1397/07
T 1994/07
T 0877/08
T 1877/08
T 2436/09
T 0146/10
T 1089/10
T 0583/11
T 2525/11
T 1121/12
T 0915/93
T 0955/93
T 1053/93
T 0379/94
T 0051/97
T 0682/99
T 0877/99
T 1450/14

I. European patent application No. 83 870 003.7 relating to a method for improved bovine milk production, filed on 14 January 1983 and claiming priority of 18 January 1982 from an earlier application in the United States of America, was refused by the Examining Division of the EPO by its decision dated 2 December 1987. This decision was based upon 4 claims of which Claim 1 as the only independent claim reads as follows:

"A method for increasing milk production by a cow which comprises administering to said cow, in an amount effective for increasing said production, a hormone which is a polypeptide having the amino acid sequence of pituitary bovine growth hormone with the addition of an N-terminal methionyl group, said hormone having been prepared by expression of a nucleotide sequence coding for said polypeptide, said sequence having been chemically synthesized or isolated from other bovine nucleotide sequences and then replicated."

II. The stated ground for the refusal was that the subject-matter of these claims did not involve an inventive step in the light of the disclosure in

(a) Insulins, Growth Hormone and Recombinant DNA Technology edited by John L. Guerignian, Raven Press, New York, 1981 pages 117-132,

(b) Proceedings of the Cornell Nutrition Conference,Feed Manuf. 1981, pages 47-51,

(c) Nature Vol. 293, No. 5831 (1 October 1981) pages 408-411, and

(d) J. Nutr. 1981, 111(9), pages 1662-71.

The Examining Division considered that the claimed subject-matter differed from the known art represented by (b) and (d) in that recombinant bovine growth hormone instead of natural bovine growth hormone is used for increasing the milk production of cows. Recombinant bovine growth hormone is chemically different from the native hormone since it contains an additional methionine in the N-terminal position. However it was already known from (a) and (c) to use in an analogous manner recombinant human growth hormone (hGH) instead of the natural hormone for stimulating growth.

The Examining Division also found that the last paragraph of (b) so strongly suggested the use of recombinant bovine growth hormone for increasing milk production that the person skilled in the art was in a "one-way street" situation leaving this use as the only logical possibility.

III. An appeal was lodged against this decision on 9 January 1988 and the appropriate fee paid on the same date. A Statement of Grounds of Appeal was filed on 31 March 1988.

In his written submissions and at the oral proceedings on 14 February 1989 the Appellant substantially argued that this last paragraph of (b) relates to bovine growth hormone (bGH) having the same amino acid sequence as pituitary bovine growth hormone, i.e. a copy of the natural product obtained by recombinant DNA technology, and submitted a declaration by Professor Baumann, the principal author of document (b) supporting this statement. Furthermore, the Appellant pointed out that, according to the application in suit, N-Met-bGH is however used and that therefore, the person skilled in the art was not in a "one-way street" situation. He further argued that three generalisations were necessary if one were to conclude from documents A and C that it was obvious to use N-Met-bGH instead of bGH in a method for increasing milk production of a cow, since these documents relate to a different hormone (hGH, and not bGH), different animals (hypophysectomised rats, and not cows) and a different type of activity (growth promotion, and not increase of milk production). The fact that with respect to growth promotion, N-Met-hGH in hypophysectomised rats is equally active as pituitary hGH did not enable the skilled person to predict that N-Met-bGH would be active in increasing the milk production of a cow. The decision under appeal was therefore based on the knowledge of 1987 rather than on that of the priority date of 1982. Two further declarations by Dr. Krivi and Dr. Peel were filed supporting this submission.

The Appellant relied upon the decision T 02/83 (OJ EPO 6/1984, 265) and argued that a person skilled in the art would not have performed the claimed method. On the other hand, he confirmed that the test results contained in the application only reflect the higher purity of the recombinant hormone and that pure natural hormone has in fact the same activity as the recombinant bGH. He also admitted that, in the three declarations, the expression "predictability" was used in its strict scientific sense.

The Appellant requested that the decision under appeal be set aside and the patent be granted on the basis of the claims refused by the Examining Division.

At the end of the oral proceedings the decision was announced dismissing the appeal.

1. The appeal complies with Articles 106 to 108 EPC and Rule 64 and is, therefore, admissible.

2. The current version of the claims is properly based on the application document as filed and not open to formal objections. As this matter is neither disputed nor relevant to the announced decision, this need not to be explained in detail.

3. After examination of the cited prior art, the Board has reached the conclusion that the claimed subject-matter is novel. Since novelty has not been disputed by the Examining Division, it is not necessary to consider this matter in detail.

4. The closest prior art with respect to the claimed method is represented by (b) and (d) which both relate to a method for increasing the milk production of a cow by administering bGH. In these documents, natural (pituitary derived) growth hormone is used for this purpose. This hormone is obtained from bovine glands by a difficult purification process and, according to the Appellant's submission, was not sufficiently pure to obtain optimal and reliably constant results.

5. The technical problem with respect to this prior art may therefore be seen in providing an improved method for increasing the milk production of a cow.

According to the application in suit this problem is solved by administering recombinant N-Met-bGH instead of natural bGH. From the comparative data contained in the worked example (cf page 9 of the description), it can be seen that, in cows receiving the natural bGH, a 12.2% increase in milk production was observed, whereas, by administering the recombinant N-Met-bGH, an increase of 14% was obtained. The difference was statistically significant on the 95% probability level. Therefore, the technical problem underlying the application is plausibly solved.

6. In order to solve this problem, the person skilled in the art had a number of possibilities at hand. It can be seen from the description, page 1, lines 4 to 16, that not only the administration of bGH, but also the administration of other hormones such as prolactin, thyrotropin releasing hormone, thyroid stimulating hormone, estrogen or other materials such as prostaglandins or caseinate materials have also been envisaged as well as dietary optimisation, light cycle manipulation or udder massage.

Therefore, the present case in the Board's view does not belong to the extremely exceptional cases to which the decision T 192/82 (OJ EPO 9/1984, 415; "one-way street" situation) relates. Furthermore, even if the administration of bGH would have been the only method for increasing the milk production of a cow and the administration of recombinant bGH would have been the only reasonable way of improving this method as recommended in (b), this would leave a number of possibilities open since "recombinant bGH" may be produced by different techniques and does not necessarily possess the N-terminal methionine residue.

7. According to the Board's jurisprudence, the question to be answered when assessing inventive step is, as the Appellant rightly submits, whether a person skilled in the art would have considered the claimed method (see the decision T 02/83, OJ EPO 6/1984, 265, especially item 7 on page 270) in the expectation of some improvement or advantage in respect of the closest prior art represented by (b) and (d).

7.1. In the Board's view, the last paragraph of (b) contains a clear suggestion to choose a bGH produced by recombinant DNA technology for improving the milk production of a cow, since it is a general goal of recombinant DNA technology to provide high quantities of pure proteins which are otherwise only available with difficulty and in insufficient quantities from natural sources. In fact, this technology was developed in order to satisfy this need.

However, recombinant DNA technology does not necessarily yield the desired protein with an additional N-terminal methionine residue. For instance the DNA sequence corresponding to the desired protein may be added to the DNA sequence corresponding to a protein normally produced in the cell to be genetically modified. This cell will then produce a fusion protein containing both amino acid sequences which would be separated later on, e.g. by enzymatic cleavage. Another widely used method, however, is to incorporate the DNA sequence corresponding to the desired protein modified by the addition of the start codon (ATG) into E. Coli bacteria (see C, the summary of the beginning of the article). This method normally yields the desired protein carrying an additional methionine at the amino end. An identical copy of the natural protein may then be obtained by the additional step of removing the N-terminal methionine by enzymatic or chemical methods.

7.2. The production of recombinant bGH via a fusion protein would have first required the preparation of bacteria capable of producing such proteins. This is in principle possible, but very time-consuming. This was confirmed by the Appellant at the oral proceedings. N-Met-bGH however was more easily available because the required genetically modified bacteria already existed, see GB-A-1 565 190 (cited in the applicaiton in suit, in the paragraph bridging pages 3 and 4). Removal of the terminal methionine from the available product, however, would also have included additional reaction and purification steps.

It is clear that such additional steps would take away a considerable part of the benefit involved in the use of the recombinant hormone instead of the natural bGH. Therefore, while this was not the only possibility in the sense of the "one-way street" situation underlying the decision T 192/82, in the Board's judgement there was a strong incentive to avoid such further steps or independent synthesis and to use the available product without further modification, at least if plausible reasons existed to expect that the desired improvement would be obtained.

7.3. This requirement is met since it is stated in (c), page 410 on the bottom of the right column that the authors of this article were not really surprised to find that the N-terminal methionine in N-Met hGH did not affect the biological activity because it was already known that in the natural hormone, which is not a homogeneous protein, the amino end is partially blocked, probably by an acetyl group. Similarly the expression "bovine growth hormone" is not applied to one single protein, but to a mixture of four main components (see page 4 of the amended description submitted on 15.5.1985). One of the modifications in the natural hormone is at the amino end which may be Phe or Ala-phe. In the latter case the amino acid sequence comprises 191 instead of 190 amino acids. Thus, in natural bGH the N-terminal Phe may also be acylated by an alanyl group, and the person skilled in the art had sound reasons to expect that the replacement of this alanine by methione would not affect the biological activity.

7.4. The person skilled in the art also had plausible reasons to expect a certain increase in activity in comparison with the natural hormone, since such an increase was suggested in (a) for the replacement of natural hGH by recombinant hGH (see the Chapter headed "Purity of bacteria-derived hGH, especially the sentence bridging pages 119 and 121) and was explained by the higher purity of the recombinant material. Therefore, the test results reported in the application in suit are not surprising, but only a confirmation of these expectations.

7.5. Furthermore, it was not the first time that a recombinant growth hormone containing an N-terminal methionine had been used instead of the natural hormone, albeit in different animals and with respect to a different type of activity, see (c) where recombinant human growth hormone was tested for growth promoting activity in hypophysectomised rats with the aim of eventually performing clinical tests (see page 411, the first paragraph on the left column). Nevertheless in the aspects of improving the purity and availability of the natural hormone the problems underlying (c) (see the abstract) and the application in suit are identical. It is quite clear from (c) that the situation was also similar insofar as no serious scientist, who is extremely cautious in such matters, could have predicted whether or not the recombinant hormone carrying the additional N-terminal methionine would be clinically useful. However, this fact did not prevent the authors of this article from testing the product directly, since this was the only way to find out whether this would be the case. Obviously these authors found it more reasonable to carry out these experiments than to undertake the additional step of removing the N-terminal methionine in order to obtain a product which is chemically identical to the natural hormone. Therefore, the Board cannot see any sound reason why a skilled person, faced with the similar technical problem underlying the application in suit, would not have arrived at the same conclusion.

7.6. In view of this teaching, which is clearly derivable from the cited prior art, the Board is satisfied that a person skilled in the art would indeed have administered the available form of recombinant bGH, i.e. the N-Met-bGH obtained according to GB-A-1 565 190, without any modification to a cow in the reasonable expectation of obtaining the same or even a greater increase in milk production as observed when natural (pituitary derived) bGH is administered.

8. In the Appellant's opinion, the claimed method would not have been performed by a person skilled in the art because this person was not able to predict (in the strict scientific sense of this word) that N-Met-bGH would increase the milk production of a cow on the basis of documents (a) to (d) (see the three declarations submitted by the Appellant).

This opinion seems to imply that, since it was necessary to carry out a test in order to know with certainty whether or not N-Met-bGH would increase the milk production of a cow, the claimed method should have been regarded as unobvious because "obvious to try" is not the standard for assessing obviousness.

This objection is unjustified since, in accordance with patent jurisprudence, inventive step is not assessed from the view point of a highly specialised and outstanding scientist who, as is well-known, is extremely cautious with regard to unproven assumptions and, therefore, would be very reluctant to make a prediction in the absence of sufficient proof, but rather from that of the notional skilled person with his average ability and knowledge.

In the present situation, this notional skilled person was provided with a clear hint from the prior art pointing him in the direction of the claimed method, and it was only necessary to confirm experimentally that the highly probable result was in fact obtained. The necessity of exerimentally confirming a reasonably expected result does not render an invention unobvious. Absolute predictability, especially in the field of biologically active chemical compounds, is rather exceptional, but inventions relating to such compounds and their administration to living organism may nevertheless be obvious. However, if such administration were to lead to unexpected results, which is not the case here, this may provide a basis for demonstrating unobviousness.

9. In the light of these explanations, the three declarations submitted by the Appellant do not provide evidence for the unobviousness of the claimed method.

9.1. Prof. Baumann, the principal author of (b), in his declaration only states that the reference in this document was not intended to imply that N-Met-bGH would be equivalent to the pituitary bGH and that he does not believe that anyone skilled in the art in 1981 would have interpreted the comment at the end of (b) as indicating an opinion that the authors expected that any recombinant bGH would be equally effective as pituitary bGH in enhancing milk production (item 3 and item 4, last paragraph). This means that this article is silent with respect to this question, but Prof. Baumann does not expressly state that he regards this result as unexpected or surprising.

In the second paragraph of item 4, Prof. Baumann states that the only way to establish whether N-Met-bGH is equally effective as pituitary bGH would have been to test it in lactating cows. However the declaration does not say that it was not a natural step in the technical development, having regard to what is said in the preceding paragraphs to perform this test in a reasonable expectation of success and thereby to arrive at the claimed method.

9.2. The declarations of Dr. Peel and Dr. Krivi are mainly related to the question of predictability of the activity of N-Met-bGH in a strict scientific sense which is in the Board's view not critical for assessing inventive step in the present case. However, in Dr. Peels declaration some indications could be found which might have pointed away from testing recombinant bGH with the expectation of increasing the milk production of a cow. Thus, in items 2 and 3 of his declaration, Dr. Peel states that there were some indications in the literature that components other than somatotropin (bGH) were present in the natural preparations which may have contributed to the lactation enhancement. Studies had been published prior to January 1982 in which it was found that highly purified pituitary somatotropin had lost its ability to stimulate lipid mobilisation which was believed at that time to be the basis of the observed enhancement of lactation. Furthermore, at that time most of the experiments had been conducted with low producing cows and there was some doubt expressed that, given this association between lactation enhancement and the lipolytic effect, high producing cows would not experience the same degree of lactation enhancement (see item 4). However, these statements are superseded by (d), a document published in 1981 of which Dr. Peel is a co-author and which relates to the lactation enhancement of high producing cows (see the title). In this document it is stated that natural bGH in fact also enhances the milk production in the high-yielding dairy cows (see the abstract), and it can be inferred therefrom that this effect was not expected to disappear when highly purified bGH was used (see page 1163, left column, the first complete paragraph).

10. As no request has been made to consider the subject-matter of the dependent Claims 2 to 4 separately, these claims must fall together with Claim 1.

Order

ORDER

For these reasons, it is decided that:

The appeal is dismissed.

Footer - Service & support
  • Service & support
    • Website updates
    • Availability of online services
    • FAQ
    • Publications
    • Procedural communications
    • Contact us
    • Subscription centre
    • Official holidays
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility